文献速递胃肠动力与功能性疾病

真实世界队列中便秘型肠易激综合征与慢性特发性便秘药物停用原因与时机

Evaluating When and Why Patients Discontinue Chronic Therapy for Irritable Bowel Syndrome With Constipation and Chronic Idiopathic Constipation.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

基于密歇根大学电子病历2012-2016年启动鲁比前列酮或利那洛肽的1612例患者,分析停药原因与时机。利那洛肽总体停药风险低于鲁比前列酮(HR=0.6,95%CI 0.5-0.8),但因不耐受停药风险更高(HR=1.6),多数不耐受停药发生在治疗前3个月。

要点

  • 利那洛肽总体停药风险低于鲁比前列酮(HR=0.6,95%CI 0.5-0.8)。
  • 利那洛肽因不耐受停药风险更高(HR=1.6,95%CI 1.2-2.3),多为腹泻。
  • 两种药物因不耐受停药多发生在治疗前3个月。

核心结论

  • 患者总体停用鲁比前列酮的可能性高于利那洛肽,但利那洛肽因不耐受(主要为腹泻)停药的可能性更高。
  • 多数因不耐受导致的停药发生在治疗前3个月。

研究设计与样本

  • 观察性真实世界队列研究,基于密歇根大学电子病历2012-2016年启动鲁比前列酮或利那洛肽的患者。
  • 通过人工病历回顾确定药物起始和停止日期,构建Cox模型预测停药风险。
  • 多变量分析纳入1612例患者。

主要发现

  • 利那洛肽使用者因任何原因停药的风险低于鲁比前列酮使用者(HR=0.6,95%CI 0.5-0.8)。
  • 3个月和12个月时,鲁比前列酮总体停药率分别为23%和43%,利那洛肽分别为14%和24%。
  • 治疗第一年内,两种药物因不耐受停药超过半数发生在最初3个月。
  • 利那洛肽使用者更可能因不耐受停药(HR=1.6,95%CI 1.2-2.3),但较少因疗效不足停药(HR=0.5,95%CI 0.4-0.8)。
  • 相对于利那洛肽,肠易激综合征诊断增加鲁比前列酮停药风险(HR=1.4,95%CI 1.1-1.6)。

临床怎么用

  • 个体化治疗选择时可考虑不同药物停药风险差异。
  • 告知患者长期结局及早期不耐受停药可能性,尤其是前3个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: To inform the patient-centered discussion regarding comparative outcomes with irritable bowel syndrome/chronic idiopathic constipation pharmacotherapy, we evaluated reasons and timing of discontinuation of FDA-approved pharmacotherapy for irritable bowel syndrome and chronic idiopathic constipation in a large observational real-world cohort. METHODS: We identified patients initiating lubiprostone or linaclotide within the University of Michigan Electronic Medical Record (2012-2016). Medication start and stop dates were determined in manual chart review including detailed review of all documentation including office notes and telephone encounters. A Cox model was constructed to predict the hazard of discontinuation. RESULTS: On multivariate analysis of 1,612 patients, linaclotide users had a lower risk of discontinuing therapy than lubiprostone users for any reason (hazard ratio [HR] = 0.6, 95% confidence interval [CI] 0.5-0.8). At 3 and 12 months, the overall discontinuation rates were 23% and 43% for lubiprostone compared with 14% and 24% for linaclotide. Over the first year of therapy, more than half of discontinuations due to intolerance occurred in the first 3 months for both drugs. Linaclotide users were more likely to discontinue due to intolerance (HR = 1.6 [95% CI, 1.2-2.3]) but less likely to discontinue due to insufficient efficacy of therapy (HR = 0.5 [95% CI, 0.4-0.8]). IBS diagnosis increased the hazard of discontinuation of lubiprostone relative to linactolide (HR = 1.4, 95% CI, 1.1-1.6). Loss of prescription drug coverage remained a common reason for discontinuation over the first year of therapy. DISCUSSION: Individuals appear more likely to discontinue lubiprostone than linaclotide overall, but more likely to discontinue linaclotide compared with lubiprostone due to intolerance (mostly diarrhea). Most discontinuations due to intolerance occur in the first 3 months. These results may be useful in individualized treatment selection and enhancing patient knowledge regarding long-term outcomes.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Shah ED, Suresh S, Jou J, et al. Evaluating When and Why Patients Discontinue Chronic Therapy for Irritable Bowel Syndrome With Constipation and Chronic Idiopathic Constipation. Am J Gastroenterol. 2020. PMID: 32022721. doi:10.14309/ajg.0000000000000530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。